Actavis Inc.

Watson Pharmaceuticals, Inc. is Now Actavis, Inc. (PICTURE)

Watson Pharmaceuticals, Inc. is Now Actavis, Inc. (PICTURE)
Paul Bisaro, President and CEO of Actavis, center, rang the closing bell at the New York Stock Exchange on Thursday 24 January 2013, signaling that the company had started trading under a new symbol NYSE:ACT. / Further text by ots and under www.presseportal.ch. The use of this picture is for editorial... mehr

Zug, Switzerland (ots) -

- Company Begins Trading as "ACT" 
- Multi-year Rebranding Campaign Underway
- Strong outlook for continued long term growth 

Watson Pharmaceuticals, Inc. the parent company of Actavis announced last Thursday that the company has adopted Actavis, Inc. (NYSE:ACT) as its new global name and has begun trading under a new symbol - ACT - on the New York Stock Exchange.

Picture: http://www.presseportal.ch/de/pm/100050704/?langid=2

The company first announced its intention to change its name last year, following its acquisition of the Actavis Group. The combination created the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.

Actavis has initiated a multi-year rebranding campaign that will guide the transition of its facilities, operations and commercial presence around the world to the Actavis name and a new logo, uniting all 17,000 employees under a single name, trademarked and protected around the world.

Actavis' International headquarters in Zug and its sales and marketing operation in Switzerland, Germany and Austria will soon be rebranded to the new distinctive logo of the Global Company, designed by the leading global identity firm Lippincott.

"With operations in more than 60 countries and a top 10 position in over 33 markets, Actavis is a dynamic global player that is recognized worldwide as a leader in providing high-quality pharmaceuticals," said Paul Bisaro, President and CEO of Actavis. "As we move forward into this exciting future for our company, we are committed to continuing the rapid and seamless execution of our integration planning efforts to provide maximum value to all of our customers and shareholders around the world."

During an investor day in New York City on Friday, January 25, the company also announced that non-GAAP earnings per diluted share are expected to be at the high-end of the previously forecasted range of $5.85 to $5.95, an increase of 25 percent over 2011 full year non- GAAP earnings. The Company expects full year 2012 revenues of approximately $5.9 billion, an increase of 29 percent over 2011.

"2012 was a landmark year for our Company as we continued our evolution into a global specialty pharmaceutical leader," said Bisaro. "Total revenue grew at approximately 29 percent, non-GAAP earnings per share grew an exceptional 25 percent and cash flow from operations was in excess of $600 million."

The Company's strategy in 2013 is to drive worldwide growth across its global business. It intends to focus on improving its position in key markets and further expand its portfolio with a special emphasis on broadening its injectable and OTC businesses in international markets.

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at: http://www.actavis.com

Forward-Looking Statement

Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with financial projections; successful integration of the legacy Actavis acquisition and the ability to recognize the anticipated synergies and benefits of the legacy Actavis acquisition; the difficulty of predicting the timing and outcome of pending or future litigation and government investigations and risks that an adverse outcome in such litigation or investigations could render Actavis liable for substantial damages or penalties; risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities or agencies; the impact of competitive products and pricing; risks related to fluctuations in foreign currency exchange rates; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; market acceptance of and continued demand for Actavis' products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2011 and Actavis' Quarterly Report on Form 10-Q for the period September 30, 2012 (such periodic public filings having been filed under the "Watson Pharmaceuticals, Inc." name). Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

Contact:

Elisabet Hjaltadottir
Phone: +354-860-3959



Weitere Meldungen: Actavis Inc.

Das könnte Sie auch interessieren: